Pulse Biosciences (NASDAQ:PLSE) Price Target Raised to $64.00

Pulse Biosciences (NASDAQ:PLSE) had its price objective upped by equities researchers at Needham & Company LLC from $58.00 to $64.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC‘s target price indicates a potential upside of 20.60% from the stock’s current price.

A number of other research analysts have also issued reports on PLSE. BTIG Research started coverage on Pulse Biosciences in a report on Wednesday, September 23rd. They issued a “buy” rating and a $70.00 target price for the company. Oppenheimer upped their price target on Pulse Biosciences from $35.00 to $60.00 and gave the stock an “outperform” rating in a report on Tuesday, October 13th. Canaccord Genuity Group raised their price target on Pulse Biosciences from $43.00 to $58.00 and gave the company a “buy” rating in a research note on Tuesday, October 6th. Mizuho set a $55.00 price objective on Pulse Biosciences in a report on Tuesday, October 13th. Finally, Freedom Capital upgraded Pulse Biosciences to a “strong-buy” rating in a research report on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $61.40.

Pulse Biosciences Stock Down 7.0%

Shares of PLSE opened at $53.07 on Friday. Pulse Biosciences has a fifty-two week low of $12.56 and a fifty-two week high of $58.90. The firm’s 50 day moving average price is $51.45 and its 200 day moving average price is $32.08.

Pulse Biosciences (NASDAQ:PLSE) last released its earnings results on Thursday, November 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.01). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.52 million. During the same quarter last year, the company earned ($0.29) earnings per share. Pulse Biosciences’s quarterly revenue was down 54.1% compared to the same quarter last year. On average, equities research analysts forecast that Pulse Biosciences will post -1.34 EPS for the current fiscal year.

Insider Buying and Selling at Pulse Biosciences

In other news, COO Liane Teplitsky acquired 1,001 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was acquired at an average cost of $49.95 per share, with a total value of $49,999.95. Following the completion of the acquisition, the chief operating officer owned 4,095 shares of the company’s stock, valued at $204,545.25. The trade was a 32.35% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders purchased 4,095 shares of company stock valued at $199,931 over the last three months. 74.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Pulse Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of the business. Osterweis Capital Management Inc. acquired a new stake in Pulse Biosciences during the 2nd quarter worth $28,000. Sterling Capital Management LLC increased its stake in Pulse Biosciences by 844.6% in the third quarter. Sterling Capital Management LLC now owns 614 shares of the company’s stock valued at $31,000 after purchasing an additional 549 shares during the period. Jupiter Topco LLC acquired a new position in Pulse Biosciences in the second quarter valued at $241,000. Axxcess Wealth Management LLC acquired a new position in Pulse Biosciences in the third quarter valued at $242,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Pulse Biosciences in the second quarter valued at about $290,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc (NASDAQ:PLSE) is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue.

The company’s principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions.